-+ 0.00%
-+ 0.00%
-+ 0.00%

Basilea Raises 2026 Operating Profit Forecast to CHF 115 Million From CHF 70 Million

PUBT·10/27/2026 06:00:49
Listen to the news
Basilea Raises 2026 Operating Profit Forecast to CHF 115 Million From CHF 70 Million
  • Basilea raised its 2026 operating profit forecast to about CHF 115 million from CHF 70 million.
  • Expected Cresemba and Zevtera-related revenue increased to about CHF 250 million from CHF 210 million, reflecting stronger Cresemba growth.
  • Milestone income is now projected at about CHF 65 million, up from CHF 35 million.
  • Total revenue is forecast at about CHF 310 million, representing 33% growth.
  • The 2026-2030 cumulative cash flow target from Cresemba and Zevtera rose to CHF 650 million from CHF 600 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270200PRIMZONEFULLFEED1001280021) on October 27, 2026, and is solely responsible for the information contained therein.